Jaka jest cena za Polydex Pharmaceuticals Limited (POLXF)

Cena za Polydex Pharmaceuticals Limited (POLXF) wynosi $1.99

Jaka jest kapitalizacja rynkowa dla Polydex Pharmaceuticals Limited (POLXF)

Kapitalizacja rynkowa dla Polydex Pharmaceuticals Limited (POLXF) wynosi $6.82M

Zyski Polydex Pharmaceuticals Limited (POLXF)

Polydex Pharmaceuticals Limited (PPL), a Toronto, Canada-based company, was incorporated in 1979 and initially operated as Polydex Chemicals Limited before adopting its current name in March 1984. PPL specializes in the research, development, manufacturing, and global marketing of biotechnology-derived products for the human pharmaceutical sector. Beyond its human health focus, PPL also produces vital pharmaceutical intermediates for the veterinary industry. Its core product line centers on dextran and its various derivatives. Notable examples include iron dextran, a compound administered to newborn pigs to combat anemia, and dextran sulphate, a specialized chemical derivative crucial for biotechnology applications and the broader pharmaceutical sector. Furthermore, the company is actively developing Ushercell, a high molecular weight cellulose sulphate. This innovative product is designed for topical vaginal use, primarily aimed at preventing the transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies. PPL's portfolio further extends to supplying ferric hydroxide and hydrogenated dextran solutions. Products reach the market through a combination of independent distributors, wholesalers, and direct sales channels to various companies.

Rok	Zyski	Zmień
Za mało danych dla podanych dat.

Rok

Zyski

Zmień

Za mało danych dla podanych dat.

Firma	Zyski	Różnica w zyskach	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$3.01B	-	BE

Firma

Zyski

Różnica w zyskach

Kraj